- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Propanc Biopharma, Inc.: Propanc Biopharma Investigates "Mesenchymal Drift" to Reverse Chronic Diseases Defined by Altos Labs | 109 | GlobeNewswire (Europe) | MELBOURNE, Australia, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company developing novel treatments for chronic diseases... ► Artikel lesen | |
| 01.12. | Propanc Biopharma: Aktie steigt nach Patentanträgen für resistente Krebstherapien | 2 | Investing.com Deutsch | ||
| 01.12. | Propanc Biopharma, Inc.: Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis | 1 | GlobeNewswire (USA) | ||
| PROPANC BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 17.11. | Propanc Biopharma, Inc. GAAP EPS of $0.39 | 1 | Seeking Alpha | ||
| 17.11. | Propanc Biopharma, Inc.: Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results | 263 | GlobeNewswire (Europe) | MELBOURNE, Australia, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company developing novel treatments for recurrent and... ► Artikel lesen | |
| 14.11. | Propanc Biopharma, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 10.11. | Propanc Biopharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 10.11. | Propanc Biopharma secures up to $100 million private placement | 1 | Seeking Alpha | ||
| 10.11. | Propanc Biopharma secures $1 million initial investment from Hexstone | 3 | Investing.com | ||
| 10.11. | Propanc Biopharma secures up to $100 million investment from Hexstone | 1 | Investing.com | ||
| 10.11. | Propanc Biopharma, Inc. Secures up to $100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company's R&D Pipeline | 1 | GlobeNewswire (USA) | ||
| 04.11. | Propanc Biopharma plant Übernahme von Unternehmen für digitale Vermögenswerte | 8 | Investing.com Deutsch | ||
| 04.11. | Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV) | 3 | GlobeNewswire (USA) | ||
| 15.10. | Propanc Biopharma announces up to $100M strategic financing from Hexstone Capital | 2 | Seeking Alpha | ||
| 15.10. | Propanc Biopharma, Inc.: Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital | 265 | GlobeNewswire (Europe) | MELBOURNE, Australia, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. ("Propanc" or the "Company") is pleased to announce it has entered into a strategic financing agreement of up to $100... ► Artikel lesen | |
| 14.10. | Propanc Biopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.10. | Propanc Biopharma meldet nach NASDAQ-Listing finanzielle Trendwende | 1 | Investing.com Deutsch | ||
| 07.10. | Propanc Biopharma reports major financial turnaround after Nasdaq uplisting | 1 | Investing.com | ||
| 07.10. | Propanc Biopharma reports major financial transformation after Nasdaq listing | 1 | Investing.com | ||
| 07.10. | Propanc Biopharma meldet finanzielle Transformation nach NASDAQ-Listing | - | Investing.com Deutsch |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,430 | -3,00 % | EQS-NVR: Evotec SE: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Evotec SE
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Evotec SE: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem... ► Artikel lesen | |
| QIAGEN | 39,935 | -1,19 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| AMGEN | 283,50 | +0,07 % | BMO Capital Lifts Amgen (AMGN) Price Target as MariTide Outlook Strengthens | ||
| BIOFRONTERA | 2,730 | +0,74 % | Biofrontera schließt Phase-1-Studie für erweitertes Anwendungsgebiet von Ameluz ab | ||
| CRISPR THERAPEUTICS | 49,600 | +0,81 % | Crispr Therapeutics pares loss amid takeover speculation | ||
| BIONXT SOLUTIONS | 0,429 | +0,70 % | BioNxt unterzeichnet Absichtserklärung zum Erwerb von 100% der IP-Rechte und zur gemeinsamen Entwicklung einer sublingualen Arzneimittelformulierung für Chemotherapie- und Immunsuppressionsbehandlungen | Vancouver, BC / ACCESS Newswire / 1. Dezember 2025 / BioNxt Solutions Inc. (CSE: BNXT) (OTCQB: BNXTF) (FSE: BXT), ein Innovator im Bereich der Bioscience, der sich auf fortschrittliche Systeme... ► Artikel lesen | |
| NOVONESIS | 53,30 | -1,19 % | Novonesis (Novozymes A/S): Novonesis delivered 8% organic sales growth in the first nine months of 2025 | Novonesis delivered 8% organic sales growth in the first nine months of 2025 and narrowed full-year outlook upwards. COPENHAGEN, Denmark - November 6, 2025. Novonesis delivered 8% organic sales growth... ► Artikel lesen | |
| TEMPUS AI | 66,50 | +0,76 % | Is Tempus AI the Next Big Artificial Intelligence Stock to Buy? | ||
| GENMAB | 272,50 | +0,07 % | Genmab: Phase 3 Trial Shows EPKINLY + R2 Cuts Progression Risk By 79% And Achieves 95% ORR In FL | WASHINGTON (dpa-AFX) - Genmab A/S (GMAB) announced primary results from the pivotal Phase 3 EPCORE FL-1 study, evaluating fixed-duration EPKINLY (epcoritamab-bysp) in combination with rituximab... ► Artikel lesen | |
| TREVENA | 2,280 | -40,00 % | Hollywood Changemaker Oliver Trevena Joins Little Kitchen Academy as Investor | LOS ANGELES, CA / ACCESS Newswire / August 21, 2025 / Little Kitchen Academy (LKA), the premier Montessori-inspired cooking academy for children and teens ages 3-18, is proud to announce that Oliver... ► Artikel lesen | |
| EXACT SCIENCES | 87,80 | +1,16 % | $100 Invested In Exact Sciences 15 Years Ago Would Be Worth This Much Today | ||
| TME PHARMA | 0,064 | 0,00 % | TME Pharma announces receipt of agreements in principle to extend certain bond agreements | TME Pharma announces receipt of agreements in principle to extend certain bond agreements Berlin, Germany, November 17, 2025, 08.00am CET - TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage... ► Artikel lesen | |
| CYTODYN | 0,268 | +11,67 % | CytoDyn Inc.: CytoDyn Announces Resolution of Class Action Lawsuit | VANCOUVER, Washington, Dec. 01, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized... ► Artikel lesen | |
| IMMUNIC | 0,584 | +1,39 % | EQS-News: Immunic AG: Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December
26.11.2025 / 12:30 CET/CEST
The... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,710 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update | Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells-the second neuro map designed to accelerate treatments for a wide range of neurological... ► Artikel lesen |
Das Unternehmen PROPANC BIOPHARMA INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,839 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PROPANC BIOPHARMA INC finden Sie auf Wallstreet Online.